Four-Pronged attack tested against aggressive stomach cancers
NCT ID NCT01191697
Summary
This study tested whether combining two chemotherapy drugs with two targeted antibody drugs was safe and effective for people with advanced HER2-positive stomach or esophageal cancer. It involved 37 adults whose cancer had spread and who had not received these specific drugs before. The goal was to see if this four-drug combination could shrink tumors and control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.